NHS Crisis Affecting
Once again, the ‘winter crisis’ has forced NHS hospitals to
cancel many non-emergency operations. Tens of thousands of interventions such
as knee or hip replacements will be postponed to make room for acute A&E
patients. See the following article for further details: https://www.theguardian.com/society/2018/jan/02/nhs-hospitals-told-to-take-unprecedented-measures-amid-winter-crisis
Or this one: http://www.telegraph.co.uk/news/2018/01/02/nhs-hospitals-ordered-cancel-routine-operations-january/
With the general unwillingness in the NHS to fund certain
treatments, often as a result of questionable NIHCE guidelines - Viscosupplementation
being an example of one such restriction - patients suffering pain and
restricted mobility due to Osteoarthritis are finding themselves in double
jeopardy. Stabilising amelioratory treatment in the form of intra-articular injections
of Sodium Hyaluronate (Viscosupplementation) into a joint affected by mild to
moderate osteoarthritis (OA) is no longer offered in many Primary Care
Organisations, but when the degenerative changes become so pronounced that
surgery is required, many patients fall victim to cancellation and postponement
of their elective procedures due to seasonal pressures on hospitals. So how can
these OA patients be helped?
Services Come to the Rescue
An increasing number of patients are turning to non-NHS
clinicians, such as musculoskeletal (MSk) experts, to treat and manage their OA
and other MSk conditions. Expert clinicians such as Extended Scope
Physiotherapists are in a unique position to help, because they can offer
patients the very treatments that the NHS can’t or won’t provide.
One of these treatments, Viscosupplementation, has been
shown to delay the need for total knee replacement (TKR) and could therefore be
the solution for many OA patients. A recently published retrospective
longitudinal study1 involving knee osteoarthritis patients using
medico-administrative databases in France (Cox model analysis) by A Delbarre et al. entitled “Do
intra-articular hyaluronic acid injections delay total knee replacement in
patients with osteoarthritis” showed that “approximately 16% of patients treated with IA HA [intra-articular hyaluronic acid] injections survived more
than 1,500 days (4.1 years) without TKR compared with 8% of patients not
treated with HA.” Another study by A Altman which analysed a large US Health
Claims Database came to similar conclusions2.
OSTENIL® injections are licensed as medical devices and do
not require a physician to prescribe, or a Consultant to administer. Instead,
local MSk triage services can offer OSTENIL® PLUS injections as a cost
effective solution, providing GPs with an alternative patient treatment
pathway, helping avoid unnecessary secondary care referrals - and the
associated tariff fee - which would more than cover the cost of the injection.
As a result, not only would the ever growing demand on secondary care be
attenuated, patient waiting times could be reduced, and clinical outcomes
1 Delbarre A, et al. (2017) Do intra-articular hyaluronic acid injections delay total knee replacement in patients with osteoarthritis – A Cox model analysis. PLOS ONE 12(11): e0187227. https://doi.org/10.1371/journal.pone.0187227
2 Altman R, Lim S, Steen RG, Dasa V (2015) Hyaluronic Acid Injections Are Associated with Delay of Total Knee Replacement Surgery in Patients with Knee Osteoarthritis: Evidence from a Large U.S. Health Claims Database. PLoS ONE 10(12): e0145776. pmid:26694145 https://doi.org/10.1371/journal.pone.0145776
Special Offer & Get Your Clinic Listed on “Find An Expert”
If you are a member of BASEM, ACPOMIT or SOMM, have completed joint injection training and would like to offer OSTENIL® injections to your patients, we would like to hear from you. We want to offer you the following package deal:
- Free listing on our “Find An Expert” page with a link to your business. We want to extend our expert clinician database as a service to patients and will direct them to you when they contact us for help.
- During January 2018: Special discount of 15% free stock on all OSTENIL® orders, minimum of 10x syringes per order.
- Thereafter: 10% free stock on all orders of 10x syringes or more.
- Free promotional posters, office stationery/ pens and a ‘phone/tablet charger power bank for you, and Patient Information Leaflets to inform your patients of the benefits of Ostenil injections.
We look forward to hearing from you.
Your Team at TRB Chemedica UK.